NewsRoom Articles - Page 102 of 225

FridayDec 02, 2022 11:59 am

Research Discovers That Survivors of Pediatric Cancer Are Prone to Premature Aging

Every year, an estimated 400 children and adolescents aged 19 and under are diagnosed with cancer. Leukemia, brain tumors, solid tumors such as neuroblastomas and lymphomas tend to be the most common types of pediatric cancer, with more than 80% of patients in high-income nations such as the United States receiving treatment. Even though pediatric cancer treatment can be quite cost intensive, childhood cancer can generally be cured via surgery, radiotherapy, chemotherapy and generic medicines. However, a recent study has revealed that patients who survive pediatric cancer aren’t completely out of the woods even after they are in remission. The…

ThursdayDec 01, 2022 9:00 am

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023 The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its Nasal Device, and the expansion of its executive team It looks to take advantage of the meeting to draw stockholders' views and opinions on specific topics while also offering them a platform to contribute to…

WednesdayNov 30, 2022 12:38 pm

Researchers Look to AI to Improve Organ Transplant Processes

Artificial intelligence (AI) is a relatively novel technology with the potential to revolutionize not just the IT industry but a whole slew of sectors. This technology leverages the ability of computer algorithms to analyze enormous data sets and learn from features or patterns in the data. AI technology is now being deployed in various industries, including the medical field. A few years ago, researchers found that AI systems could diagnose eye diseases as accurately as trained physicians. Earlier this year, further research also revealed that AI and machine learning could be used to diagnose heart diseases by analyzing the network…

TuesdayNov 29, 2022 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030 BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company…

TuesdayNov 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need” Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness The neuropharmaceutical market is forecast to have a great deal of…

TuesdayNov 29, 2022 10:12 am

Four Facts You Need to Know About Brain Cancer

Brain cancer is one of the most debilitating conditions on the planet. Affecting an estimated 700,000 Americans, the condition has no cure and is often associated with poor negative outcomes, especially when diagnosed late. The main treatment options for brain cancer are surgery, chemotherapy and radiation, and the treatments tend to be more effective if the tumor is spotted and addressed in the early stages. Overall, brain tumors terrify most people because they can grow right under your nose and are often diagnosed when it is too late. RUSH chief of Medical Neuro-Oncology Seam Grimm, MD, recently discussed some of…

MondayNov 28, 2022 9:46 am

Type 2 Diabetes Patients Are Diagnosed Late If They Develop Cancer

Early diagnosis is critical for positive outcomes in cancer. Although there is no effective cure for cancer, early diagnosis allows physicians to deploy treatments such as surgery, radiation and chemotherapy that can reduce the size of the tumor and increase life expectancy. Research shows that nearly one-half of people who develop cancer are diagnosed late, reducing the chances of successful treatment and limiting their survival chances. A recent study by postdoctoral researcher Dr. Anna Jansana has revealed that people with type 2 diabetes are more likely to receive late diagnoses if they develop a type of cancer that isn’t screened…

MondayNov 28, 2022 9:06 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has…

WednesdayNov 23, 2022 11:15 am

MetAlert Inc. (MLRT) Is ‘One to Watch’

MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRT The company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millions The recent pandemic created an emphasis on health monitoring, especially for at-risk consumers/patients The recent pandemic negatively impacted the supply chain and shipping, creating a backlog of orders, but recent months’ activity suggests that the supply chain and shipping issues will be resolved…

WednesdayNov 23, 2022 10:11 am

Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment

For quite a while, experts have described concussions and traumatic brain injuries as a “silent epidemic” affecting millions across America. Concussions usually occur when an indirect or direct blow to an individual’s head causes their brain to slam against the inside of their skull and sustain damage. These injuries can be hard to treat because they usually don’t display symptoms at the time of injury. In some cases, symptoms can take days or even weeks to manifest, and it is often the victim's family and friends who notice changes in personality first, such as mood swings, irritability, anger and general…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Research Discovers That Survivors of Pediatric Cancer Are Prone to Premature Aging

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

Researchers Look to AI to Improve Organ Transplant Processes

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

Four Facts You Need to Know About Brain Cancer

Type 2 Diabetes Patients Are Diagnosed Late If They Develop Cancer

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

MetAlert Inc. (MLRT) Is ‘One to Watch’

Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search